Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
Rhea-AI Summary
Fennec Pharmaceuticals (NASDAQ: FENC) will release full year and fourth quarter 2025 financial results before U.S. markets open on March 24, 2026.
Management will host an 8:30 a.m. ET conference call and webcast the same day; a replay will be archived on the company website for 30 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves with 1 up and 3 down in the momentum set; IMMP and others are down around the sector’s median move of about -1.3%, while VNDA is up, suggesting broader but directionally mixed biotech dynamics.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 16 | Patent settlement | Positive | +5.0% | Settlement with Cipla limiting generic PEDMARK entry until September 1, 2033. |
| Mar 04 | Clinical collaboration | Positive | +2.5% | Real-world PEDMARK study with Tampa General Hospital Cancer Institute. |
| Feb 20 | Clinical data update | Positive | -0.5% | Real-world PEDMARK data in adult head & neck cancer patients. |
| Dec 26 | Investor share sale | Negative | -4.9% | Southpoint sold 1,000,000 shares, cutting its stake to about 8%. |
| Dec 09 | Investigator trial | Positive | +1.3% | City of Hope Phase I trial of PEDMARK in metastatic testicular tumors. |
Recent news usually aligned with price moves, with only one divergence in five events.
Over the past several months, Fennec reported multiple PEDMARK-related milestones and ownership changes. A March 16, 2026 settlement with Cipla extended generic entry limits to September 1, 2033, and a March 4, 2026 collaboration with Tampa General Hospital advanced real‑world data generation. Earlier, new adult head and neck cancer data on February 20, 2026 and an investigator‑sponsored testicular cancer trial on December 9, 2025 expanded the clinical footprint. A December 26, 2025 Southpoint share sale weighed on the stock.
Market Pulse Summary
This announcement sets expectations for Fennec’s full year and Q4 2025 report on March 24, 2026, including a management conference call and webcast. In context of recent PEDMARK milestones, litigation settlement, and real‑world data updates, investors may focus on revenue traction, operating trends, and guidance commentary. Monitoring subsequent SEC filings, insider activity, and follow‑up clinical disclosures around the call date could be important for understanding the evolving risk–reward profile.
AI-generated analysis. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2025 financial results before the opening of the U.S. financial markets on Tuesday, March 24, 2026. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.
| Conference Call & Webcast Detail: | ||
| Date: | Tuesday, March 24, 2026 | |
| Time: | 8:30 a.m. Eastern Time | |
| Webcast Link: | https://edge.media-server.com/mmc/p/3crq898e | |
| Participant Link: | https://register-conf.media-server.com/register/BIb7d9f04377fd4b9cb7b005d167555402 | |
To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and.; PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit www.fennecpharma.com and follow on LinkedIn.
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
lrocco@elixirhealthpr.com
FAQ
When will Fennec Pharmaceuticals (FENC) report full year and Q4 2025 results?
What time is the Fennec (FENC) March 24, 2026 conference call and webcast?
How can investors access the Fennec (FENC) live webcast for March 24, 2026?
Will Fennec (FENC) provide a replay of the March 24, 2026 earnings webcast?
Do shareholders need to register to join Fennec (FENC) conference call on March 24, 2026?
